SCHEMBL14636601

SCHEMBL14636601

COC(=O)C(CO)NCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.56
ALDH1A1 P00352 2/20 0.55
THRB P10828 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
HSD17B10 Q99714 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.51
MAPT P10636 1/20 0.51
TRPM8 Q7Z2W7 1/20 0.49
CA12 O43570 3/20 0.47
CA7 P43166 3/20 0.47
CA9 Q16790 3/20 0.47
CA14 Q9ULX7 3/20 0.47
POLB P06746 1/20 0.47
PDCD1 Q15116 3/20 0.46
CD274 Q9NZQ7 3/20 0.46
CA2 P00918 2/20 0.46
CA1 P00915 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5878196 1.00 ATM (0.56) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL304265 1.00 ATM (0.56) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL30354719 0.87 PDCD1 (0.55) ATMMEN1KMT2AMAPTPDCD1
SCHEMBL4560664 0.87 PDCD1 (0.55) ATMMEN1KMT2AMAPTPDCD1
SCHEMBL1508826 0.87 ATM (0.56) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL419013 0.87 ATM (0.56) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL2375646 0.87 ATM (0.68) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL7907847 0.87 ATM (0.56) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL2375644 0.87 ATM (0.68) ATMALDH1A1THRBCYP2C9CYP2C19
SCHEMBL3959739 0.87 ATM (0.68) ATMALDH1A1THRBCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119790058-A Fused cyclic KRAS inhibitors for the treatment of diseases 荣山医药股份有限公司 2025-04-08 CN disclosed
WO-2024015262-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS, INC. (US) 2024-01-18 WO disclosed
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
EP-4214214-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 EP disclosed
CN-116171280-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-05-26 CN disclosed
WO-2022058920-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 WO disclosed
CN-113666922-A Internal sulfonamide compounds and methods of use thereof 正大天晴药业集团股份有限公司 2021-11-19 CN disclosed
CN-109071471-B Internal sulfonamide compounds and methods of use thereof 正大天晴药业集团股份有限公司 2021-05-07 CN disclosed
US-9481682-B2 Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-01 US disclosed
US-20150353570-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-10 US disclosed
EP-2948458-A1 BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-12-02 EP disclosed
US-20140221333-A1 BTK INHIBITORS MERCK SHARP & DOHME B.V. (NL) 2014-08-07 US disclosed
WO-2014114185-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-07-31 WO disclosed
WO-2014113932-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-07-31 WO disclosed
US-20140206681-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. 2014-07-24 US disclosed
EP-2734529-A1 BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-05-28 EP disclosed
WO-2013010380-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-24 WO disclosed
CN-1265670-A Dipeptides and related compounds that inhibit VLA-4 mediated leukocyte adhesion ELAND PHARMACEUTICALS CO (US) 2000-09-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK1G1 ATM 1086/4885ALDH1A1 1482/4885THRB 493/4885
US-20140206681-A1 BTK INHIBITORS BTK, SYK, LYN ATM 482/4885ALDH1A1 4405/4885THRB 1390/4885
US-20150353570-A1 BTK INHIBITORS BTK, SYK, LYN ATM 482/4885ALDH1A1 4405/4885THRB 1390/4885
US-20140221333-A1 BTK INHIBITORS BTK, SYK, ABL1 ATM 314/4885ALDH1A1 4482/4885THRB 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.